Taking RNA epigenetics by Storm
Storm is tapping the nascent field of RNA epigenetics for cancer
Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer.
CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of epigenetic targets because, like DNA-modifying enzymes, they alter gene expression without changing the genetic code.
"It's the same paradigm as DNA and histone modification enzymes that have